Los Gatos, CA (PRWEB) May 29, 2015
GeneWEAVE, Inc., a clinical diagnostics company addressing multi-drug-resistant organisms (MDROs), announced that initial feasibility data supporting the use of Smarticles™ technology for same-shift bacterial detection and susceptibility testing from positive blood cultures will be presented at asm2015 on May 31, 2015 in New Orleans, LA. The Company’s Smarticles™ technology is a new class of molecular diagnostics that can quickly detect bacteria and assess antibiotic susceptibility directly from clinical samples without the need for sample preparation or organism isolation. The data being presented demonstrates that assays developed with Smarticles™ technology were able to analyze Gram-positive and Gram-negative bacteria for susceptibility to multiple classes of antibiotics as well as determine antibiotic susceptibility of a target pathogen directly from a polymicrobial positive blood culture sample matrix within 4 hours without the need for complex sample preparation.
The data will be presented on Sunday, May 31, 2015 from 10:45AM – 12:00PM in Session 014, Antimicrobial Resistance and Susceptibility Testing: Gram-Positive (Division C). The Company will also be exhibiting at Booth #143 during the meeting at the New Orleans Ernest N. Morial Convention Center and will host a Satellite Symposium at the JW Marriott New Orleans Hotel on June 1 featuring Lance R. Peterson, MD, Director of Microbiology and Infectious Diseases Research at NorthShore University HealthSystem.
“Knowing the most appropriate antibiotic to use for each individual patient’s infection is becoming more important as the levels of antibiotic resistance continue to increase worldwide. Receiving this information quickly is crucial for better patient outcomes - and in sepsis, decreasing time to appropriate treatment is a key component to reducing mortality,” said Steve Tablak, CEO at GeneWEAVE. “The data from this study supports how our Smarticles™ technology can deliver more timely susceptibility results. We are pleased with the growing evidence that supports the application of our transformative Smarticles™ technology for use in an application as important as sepsis.”
The emergence and spread of bacteria that are resistant to currently available antibiotics is a growing worldwide threat recently highlighted by multiple public health agencies including the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC). Antibiotic resistance is further complicating the treatment of infectious diseases where time is of the essence. Easy-to-use diagnostic tests that quickly identify which antibiotics will be effective for a specific infection are needed for better patient outcomes. Obtaining this data via current methods is time-consuming and labor-intensive, taking days to deliver the time-critical antibiotic susceptibility information that healthcare providers need. GeneWEAVE is using Smarticles™ technology to develop direct-from-sample susceptibility tests that will quickly rule-in appropriate antibiotic therapy within hours, so that healthcare providers will know the best treatment to use at the earliest possible moment.
GeneWEAVE, Inc., based in Los Gatos, Calif., is a privately-held in vitro diagnostics company that is advancing clinical microbiology with diagnostic solutions to aid healthcare providers in the fight against drug-resistant bacteria by enabling impactful surveillance programs, early therapy guidance and successful antibiotic stewardship. The company’s innovative and proprietary Smarticles™ technology harnesses the power of biology to rapidly detect drug resistance and measure susceptibility information without the need for enrichment, culture, or sample preparation. We call this new paradigm, “Sample-In/Susceptibility-Out.”
GeneWEAVE and Smarticles are trademarks of GeneWEAVE, Inc. All rights reserved.
Read the full story at http://www.prweb.com/releases/2015/05/prweb12748227.htm.
Copyright©2015 Vocus, Inc.
All rights reserved